Synapse Open Synapse
Biology

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

Nature Medicine · · 50 min read

This work developed and validated a computational pathology biomarker—the TROP2 normalized membrane ratio—that quantifies subcellular TROP2 localization and predicts improved progression-free and overall survival with datopotamab deruxtecan in patients with nonsquamous non-small-cell lung cancer lacking actionable genomic alterations.

Latest from Nature Medicine